SGLT2 inhibitors vs. GLP-1 agonists for kidney outcomes in patients with type 2 diabetesStudy compares the effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in patients with type 2 diabetes.